Alliance Foundation Trials, LLC (AFT) and Pfizer Inc. today announced results from the phase III PATINA trial demonstrating that the addition of palbociclib (IBRANCE) to current standard-of-care first-line maintenance therapy (following induction chemotherapy) resulted in statistically significant and clinically meaningful improvement in progression-free survival (PFS) by investigator assessment in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC).
COVID-19 pandemic has increased mental health burden on family and friends of patients
Family members and close friends of people with COVID-19 have elevated symptoms of depression and anxiety, a study from Karolinska Institutet published in The Lancet
September 22, 2023